endpts.com·Apr 10, 2026
Vivatides Therapeutics has secured $54 million in Series A funding for its preclinical research and development of siRNA and antisense oligonucleotides targeting tissues beyond the liver.
For a professional tracking biotech and AI drug discovery, the key insight is that Vivatides Therapeutics' successful $54M Series A funding highlights growing investor confidence in the potential of siRNA and antisense oligonucleotides technologies to target tissues beyond the liver, indicating a promising area for future therapeutic developments and potential collaborations.